APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 2853, the BLOCKING Act, provisions relating to amending the Hatch-Waxman Act's 180-day exclusivity structure; and S. 4348, the Food and Drug Safety and Landmark Advancements Act, Section 515, 180 Day Exclusivity Period, provisions relating to amending the Hatch-Waxman Act's 180-day exclusivity structure to prevent market blockages.
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.